Hemay007 vs infliximab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Crohn's Disease
Shared mechanism: TNF-alpha · full Crohn's Disease pipeline
Hemay007
Developed by Tianjin Hemay Pharmaceutical
NCT02603185 · Phase 1 · status unknown
This is a randomized, double-blind, placebo-controlled early-phase safety and pharmacokinetics study conducted in healthy volunteers rather than in patients with the target condition, with adverse-event monitoring as its primary endpoint rather than a measure of disease benefit. No results have been posted yet. Its registered primary outcome on ClinicalTrials.gov is "Adverse events assessments after single and multiple ascending dose administration at baseline and repeatedly until study completion". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
No aligned efficacy figure on record for this race.
infliximab · Remicade
Marketed by Johnson & Johnson
NCT00094458 · Phase 3 · completed
This meets the 'strong' test: randomized, triple-blinded (participant/investigator/outcomes assessor), active-comparator (not merely placebo) design, adequately powered (n=508), a primary endpoint that is a hard clinical measure (corticosteroid-free clinical remission via CDAI), and the primary comparisons reached statistical significance in the favorable direction for the key comparisons (combo vs AZA and IFX vs AZA).
Next expected readout: November 2026 · NCT05906576 (registry estimate)
Reported efficacy
Percentage of Participants With Corticosteriod-free Clinical Remission (Week 26): Percentage of Participants With Corticosteriod-free Clinical Remission (Week 26): Azathioprine + Placebo 30.0% vs Infliximab + Placebo 44.4% vs Infliximab + Azathioprine 56.8%; p=<0.001 (Azathioprine + Placebo vs Infliximab + Azathioprine), p=0.006 (Azathioprine + Placebo vs Infliximab + Placebo), p=0.022 (Infliximab + Placebo vs Infliximab + Azathioprine) (met)
Result source: NCT00094458
Results for Crohn's Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Hemay007 | infliximab |
|---|---|---|
| Clinical remission (induction) | —Not reported | 47.3% vs 34.1%vs Azathioprine + PlaceboNCT000944585 other results
|
| Endoscopic response (induction) | —Not reported | —Not posted · NCT00004941 |
| Clinical remission (maintenance) | —Not reported | 66% vs 54.7%vs Azathioprine + PlaceboNCT000944587 other results
|
| Endoscopic response (maintenance) | —Not reported | —Not posted · NCT00004941 |
Clinical remission (induction)
- Hemay007
- —Not reported
- infliximab
- 47.3% vs 34.1%vs Azathioprine + PlaceboNCT00094458
5 other results
- 59.8% vs 34.1% NCT00094458
- 49.1% vs 27.6% NCT00094458
- 52.1% vs 27.6% NCT00094458
- 32.5% vs 17.6% NCT00094458
- 36.7% vs 17.6% NCT00094458
Endoscopic response (induction)
- Hemay007
- —Not reported
- infliximab
- —Not posted · NCT00004941
Clinical remission (maintenance)
- Hemay007
- —Not reported
- infliximab
- 66% vs 54.7%vs Azathioprine + PlaceboNCT00094458
7 other results
- 74.1% vs 54.7% NCT00094458
- 72.2% vs 58.7% NCT00094458
- 73.1% vs 58.7% NCT00094458
- 66% vs 61.3% NCT00094458
- 69.4% vs 61.3% NCT00094458
- 47.9% vs 31.8% NCT00094458
- 60.4% vs 31.8% NCT00094458
Endoscopic response (maintenance)
- Hemay007
- —Not reported
- infliximab
- —Not posted · NCT00004941
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Hemay007: no structured comparison results are available for Crohn's Disease.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Hemay007: 0 of 4 rows · infliximab: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | infliximab |
|---|---|
| Dropout rate | 28.4%Infliximab + Azathioprinea NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3 show 9 more results34.3%Infliximab + Placebo NCT00094458 · Phase 3 · Crohn's Disease · phase 3 —W30-Infliximab + Azathioprine NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3 —W30-Infliximab + Placebo NCT00094458 · Phase 3 · Crohn's Disease · phase 3 —W50-Infliximab + Azathioprine NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3 —W50-Infliximab + Placebo NCT00094458 · Phase 3 · Crohn's Disease · phase 3 0% NCT01580670 · Phase 3 · monotherapy 13.3% NCT00805766 · Phase 3 · monotherapy 18.2% NCT00688636 · Phase 4 · registry result, not featured evidence 50% NCT00791557 · Phase na · registry result, not featured evidence |
| Discontinued due to AEs | 16.6%Infliximab + Azathioprinea NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3 show 9 more results11.8%Infliximab + Placebo NCT00094458 · Phase 3 · Crohn's Disease · phase 3 —W30-Infliximab + Azathioprine NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3 —W30-Infliximab + Placebo NCT00094458 · Phase 3 · Crohn's Disease · phase 3 —W50-Infliximab + Azathioprine NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3 —W50-Infliximab + Placebo NCT00094458 · Phase 3 · Crohn's Disease · phase 3 — NCT01580670 · Phase 3 · monotherapy 2.2% NCT00805766 · Phase 3 · monotherapy 18.2% NCT00688636 · Phase 4 · registry result, not featured evidence 50% NCT00791557 · Phase na · registry result, not featured evidence |
| Serious AEs | —Infliximab + Azathioprinea NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3 show 9 more results—Infliximab + Placebo NCT00094458 · Phase 3 · Crohn's Disease · phase 3 14%W30-Infliximab + Azathioprine NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3 16%W30-Infliximab + Placebo NCT00094458 · Phase 3 · Crohn's Disease · phase 3 1.9%W50-Infliximab + Azathioprine NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3 15.5%W50-Infliximab + Placebo NCT00094458 · Phase 3 · Crohn's Disease · phase 3 14.3% NCT01580670 · Phase 3 · monotherapy — NCT00805766 · Phase 3 · monotherapy 9.1% NCT00688636 · Phase 4 · registry result, not featured evidence 0% NCT00791557 · Phase na · registry result, not featured evidence |
| Most frequent reported AEs | a nausea 21.8% abdominal pain 13.4% fatigue 13.4% NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3 show 6 more resultsabdominal pain 9.3% nasopharyngitis 8.3% crohn's disease 5.6% NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3 double stranded dna antibody positive 50% gastroenteritis 21.4% headache 21.4% NCT01580670 · Phase 3 · monotherapy infusion reaction 18.2% (placebo 7.7%) abcess 9.1% (placebo 7.7%) bronchitis 9.1% (placebo 0%) NCT00688636 · Phase 4 · registry result, not featured evidence bone marrow suppression 50% infection 50% infusion reaction 50% NCT00791557 · Phase na · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 4 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
infliximab
show 3 more results
show 1 more result
show 15 more results
show 15 more results
show 9 more results
show 9 more results
show 13 more results
show 13 more results
show 13 more results
+ 6 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Hemay007's landscape · infliximab's landscape